Abstract
Infections are one of the well-known precipitating factors for relapses in patients with immune thrombocytopenia (ITP). Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can sometimes lead to or be associated with thrombocytopenia due to an increase in peripheral platelet destruction from inflammatory hyperactivation. Currently, we do not know if SARS-CoV-2 infection modifies the natural evolution of chronic or persistent ITP or if previous immunosuppression of patients with ITP influences the incidence and severity of coronavirus disease 2019 (COVID-19) in this group. The present study was an observational, multicentre, national series of 32 adult patients with pre-existing ITP and subsequent SARS-CoV-2 infection, collected by the Spanish ITP Group [Grupo Español de Trombocitopenia Inmune (GEPTI)].
Keywords: COVID-19; ITP; chronic; persistent; steroids; treatment.
【저자키워드】 COVID-19, Treatment, Steroids, persistent, chronic, ITP, 【초록키워드】 Treatment, coronavirus disease, Evolution, SARS-CoV-2, SARS-COV-2 infection, severity, Infection, Immunosuppression, Patient, Platelet, multicentre, incidence, group, Immune thrombocytopenia, Coronavirus-2, Inflammatory, acute respiratory syndrome, Factor, National, Hyperactivation, Spanish, collected, subsequent, increase in, influence, modify, 【제목키워드】 SARS-CoV-2, Infection, Characteristics, Patient, Spain, Immune thrombocytopenia, Coronavirus-2, acute respiratory syndrome,